Allogene Therapeutics Inc.
10/07/2024 | Press release | Distributed by Public on 10/07/2024 14:28
Amendments to Code of Ethics Form 8 K
Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.
On October 3, 2024, the Audit Committee of the Board of Directors of Allogene Therapeutics, Inc. (the "Company") adopted and approved certain amendments to the Company's Code of Business Conduct and Ethics (the "Code") that applies to all directors, officers, employees and certain consultants and contractors of the Company ("Covered Persons"). The existing Code was refreshed and updated by further enhancing and clarifying the Code's standards requiring compliance with applicable governmental laws, rules, and regulations as well as Company policies and procedures. The amendments include, among other changes: (i) changes to reflect a concurrent amendment to the Company's insider trading policy, (ii) additional expressly stated categories of information that may not be shared with competitors pursuant to antitrust laws, (iii) an additional expressly stated category of direct or indirect financial benefit that a Covered Person must consider in connection with potential conflicts of interest, (iv) changes to the procedures that must be followed prior to any Covered Person investing or participating in an outside business opportunity that is directly related to the Company's line of business, (v) expanded restrictions designed to maintain the integrity of the Company's records and public disclosures, (vi) expanded obligations related to fair dealing, (vii) expanded restrictions against giving or receiving certain gifts and entertainment, (viii) expanded requirements related to the protection and use of Company assets, (ix) an update to the scope of the Company's official spokespersons' authority with respect to media and public disclosures, (x) express requirements to comply with data privacy and cybersecurity matters, and (xi) an express requirement that Covered Persons comply with all other Company policies that are developed to support and reinforce the principles set forth in the Code.
The foregoing summary of the amendments to the Code is qualified in its entirety by the full text of the amended and restated Code of Ethics, adopted and effective October 3, 2024, which is attached hereto as Exhibit 14.1. The updated Code will also be posted on the Company's website at http://www.allogene.com under the Governance section of our Investors page as soon as practicable.